ENA713

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Alzheimer's Dementia

Conditions

Alzheimer's Dementia

Trial Timeline

Aug 1, 2012 → Jun 1, 2015

About ENA713

ENA713 is a approved stage product being developed by Novartis for Alzheimer's Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT01585272. Target conditions include Alzheimer's Dementia.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Dementia were approved

Approved (20) Terminated (2) Active (0)
DonepezilEisaiApproved
DONEPEZIL HYDROCHLORIDEEisaiApproved
Donepezil HCLEisaiApproved
Donepezil HClEisaiApproved
Donepezil HydrochlorideEisaiApproved
AriceptEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01948791ApprovedCompleted
NCT01585272ApprovedCompleted

Competing Products

20 competing products in Alzheimer's Dementia

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
GSK4527226AlectorPhase 2
29
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
simufilamCassava SciencesPhase 2
17
Remternetug + PlaceboEli LillyPhase 3
44
solanezumabEli LillyPhase 2
35
LY2886721 + PlaceboEli LillyPhase 1
29
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
39
FK962Astellas PharmaPhase 2
27
ASP0777 + PlaceboAstellas PharmaPhase 1
29
Elenbecestat + PlaceboEisaiPhase 3
32
DonepezilEisaiApproved
43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
40
Donepezil hydrochlorideEisaiPhase 3
40
Donepezil HydrochlorideEisaiPre-clinical
26